Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Steffen Appold

Showing results (31-40 of 39) with videos related to

Pageof 4
Sort By:
You have reached the last page of results.This site can display upto 39 results.
Radiotherapy and Oncology : Journal of the European Society for Therapeutic Radiology and Oncology|November 5, 2013
Applicability of the linear-quadratic formalism for modeling local tumor control probability in high dose per fraction stereotactic body radiotherapy for early stage non-small cell lung cancerMatthias Guckenberger, Rainer Johannes Klement, Michael Allgäuer, et al.
Clinical and Translational Radiation Oncology|April 18, 2019
Independent validation of tumour volume, cancer stem cell markers and hypoxia-associated gene expressions for HNSCC after primary radiochemotherapyAnnett Linge, Stefan Schmidt, Fabian Lohaus, et al.
Acta Oncologica (Stockholm, Sweden)|July 5, 2019
Inter-observer variability in target delineation increases during adaptive treatment of head-and-neck and lung cancerRudi Apolle, Steffen Appold, Henk P Bijl, et al.
Strahlentherapie Und Onkologie : Organ Der Deutschen Rontgengesellschaft ... [Et Al]|August 28, 2014
Stereotactic body radiotherapy for centrally located stage I NSCLC: a multicenter analysisDaniel H Schanne, Ursula Nestle, Michael Allgäuer, et al.
Strahlentherapie Und Onkologie : Organ Der Deutschen Rontgengesellschaft ... [Et Al]|July 15, 2025
Accelerated vs. conventionally fractionated postoperative radiotherapy of non-small cell lung cancer-final results of the prematurely terminated PORTAF trialRebecca Bütof, Lydia Koi, Steffen Löck, et al.
Radiotherapy and Oncology : Journal of the European Society for Therapeutic Radiology and Oncology|August 22, 2019
Estimation of the α/β ratio of non-small cell lung cancer treated with stereotactic body radiotherapyRainer J Klement, Jan-Jakob Sonke, Michael Allgäuer, et al.
International Journal of Radiation Oncology, Biology, Physics|March 20, 2020
Correlating Dose Variables with Local Tumor Control in Stereotactic Body Radiation Therapy for Early-Stage Non-Small Cell Lung Cancer: A Modeling Study on 1500 Individual TreatmentsRainer J Klement, Jan-Jakob Sonke, Michael Allgäuer, et al.
Oncotarget|January 10, 2018
Intratumoral heterogeneity and <i>TERT</i> promoter mutations in progressive/higher-grade meningiomasTareq A Juratli, Christian Thiede, Mara V A Koerner, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|January 5, 2018
Development and Validation of a Gene Signature for Patients with Head and Neck Carcinomas Treated by Postoperative Radio(chemo)therapyStefan Schmidt, Annett Linge, Alex Zwanenburg, et al.
Pageof 4

Showing results (31-40 of 39) with videos related to

Sort By:
Pageof 4
You have reached the last page of results.This site can display upto 39 results.
Radiotherapy and Oncology : Journal of the European Society for Therapeutic Radiology and Oncology|November 5, 2013
Applicability of the linear-quadratic formalism for modeling local tumor control probability in high dose per fraction stereotactic body radiotherapy for early stage non-small cell lung cancerMatthias Guckenberger, Rainer Johannes Klement, Michael Allgäuer, et al.
Clinical and Translational Radiation Oncology|April 18, 2019
Independent validation of tumour volume, cancer stem cell markers and hypoxia-associated gene expressions for HNSCC after primary radiochemotherapyAnnett Linge, Stefan Schmidt, Fabian Lohaus, et al.
Acta Oncologica (Stockholm, Sweden)|July 5, 2019
Inter-observer variability in target delineation increases during adaptive treatment of head-and-neck and lung cancerRudi Apolle, Steffen Appold, Henk P Bijl, et al.
Strahlentherapie Und Onkologie : Organ Der Deutschen Rontgengesellschaft ... [Et Al]|August 28, 2014
Stereotactic body radiotherapy for centrally located stage I NSCLC: a multicenter analysisDaniel H Schanne, Ursula Nestle, Michael Allgäuer, et al.
Strahlentherapie Und Onkologie : Organ Der Deutschen Rontgengesellschaft ... [Et Al]|July 15, 2025
Accelerated vs. conventionally fractionated postoperative radiotherapy of non-small cell lung cancer-final results of the prematurely terminated PORTAF trialRebecca Bütof, Lydia Koi, Steffen Löck, et al.
Radiotherapy and Oncology : Journal of the European Society for Therapeutic Radiology and Oncology|August 22, 2019
Estimation of the α/β ratio of non-small cell lung cancer treated with stereotactic body radiotherapyRainer J Klement, Jan-Jakob Sonke, Michael Allgäuer, et al.
International Journal of Radiation Oncology, Biology, Physics|March 20, 2020
Correlating Dose Variables with Local Tumor Control in Stereotactic Body Radiation Therapy for Early-Stage Non-Small Cell Lung Cancer: A Modeling Study on 1500 Individual TreatmentsRainer J Klement, Jan-Jakob Sonke, Michael Allgäuer, et al.
Oncotarget|January 10, 2018
Intratumoral heterogeneity and <i>TERT</i> promoter mutations in progressive/higher-grade meningiomasTareq A Juratli, Christian Thiede, Mara V A Koerner, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|January 5, 2018
Development and Validation of a Gene Signature for Patients with Head and Neck Carcinomas Treated by Postoperative Radio(chemo)therapyStefan Schmidt, Annett Linge, Alex Zwanenburg, et al.
Pageof 4